Jonathan Golas
Impact in
- Oncology top 5%
- HER2/EGFR in Cancer Research
- Peptidase Inhibition and Analysis
-
- Monoclonal and Polyclonal Antibodies Research
Papers in
- Oncology 6
- HER2/EGFR in Cancer Research 3
- Cancer Immunotherapy and Biomarkers 2
- Peptidase Inhibition and Analysis 1
-
- Monoclonal and Polyclonal Antibodies Research 4
- Co-authors
- Carolyn Discafani (3 shared papers)Ramaswamy Nilakantan (2 shared papers)Yu‐Fen Wang (2 shared papers)Marvin F. Reich (2 shared papers)Xiaoqing Shi (2 shared papers)Ru Shen (2 shared papers)William Hallett (2 shared papers)M. Brawner Floyd (2 shared papers)
- Journals
- Cancer Research (3 papers)Molecular Cancer Therapeutics (1 paper)Clinical Cancer Research (1 paper)Cancer Immunology Immunotherapy (1 paper)Journal of Medicinal Chemistry (1 paper)
- Partner nations
- United StatesChina
In The Last Decade
Jonathan Golas
8 papers receiving 1.2k citations
Jonathan Golas's Hit Papers
Peers
Comparison fields: 5 of 62
- Oncology 799
- Radiology, Nuclear Medicine and Imaging 289
- Genetics 115
- Pulmonary and Respiratory Medicine 284
- Hematology 77
Countries citing papers authored by Jonathan Golas
This map shows the geographic impact of Jonathan Golas's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jonathan Golas with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jonathan Golas more than expected).
Fields of papers citing papers by Jonathan Golas
This network shows the impact of papers produced by Jonathan Golas. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jonathan Golas. The network helps show where Jonathan Golas may publish in the future.
Co-authors
The 25 scholars most cited alongside Jonathan Golas, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Antitumor Activity of HKI-272, an Orally Active, Irreversible Inhibitor of the HER-2 Tyrosine Kinase Hit paper breakdown → | 2004 | 525 |
| 2 | 2005 | 258 | |
| 3 | 2017 | 165 | |
| 4 | 2005 | 123 | |
| 5 | 2019 | 97 | |
| 6 | 2017 | 35 | |
| 7 | 2015 | 5 | |
| 8 | 2020 | 1 |
About Jonathan Golas
Jonathan Golas is a scholar working on Oncology, Radiology, Nuclear Medicine and Imaging, Molecular Biology, Immunology and Allergy and Genetics, having authored 8 papers that have together received 1.2k indexed citations. Recurring topics across this work include Monoclonal and Polyclonal Antibodies Research (4 papers), HER2/EGFR in Cancer Research (3 papers), Cell Adhesion Molecules Research (2 papers), Cancer Immunotherapy and Biomarkers (2 papers), Chronic Myeloid Leukemia Treatments (1 paper), Peptidase Inhibition and Analysis (1 paper), Cancer Research and Treatments (1 paper) and Chronic Lymphocytic Leukemia Research (1 paper). The work is most often cited by research in Oncology (799 citations), Radiology, Nuclear Medicine and Imaging (289 citations), Genetics (115 citations), Pulmonary and Respiratory Medicine (284 citations) and Hematology (77 citations). Jonathan Golas has collaborated with scholars based in United States and China. Frequent co-authors include Carolyn Discafani, Ramaswamy Nilakantan, Yu‐Fen Wang, Marvin F. Reich, Xiaoqing Shi, Ru Shen, William Hallett, M. Brawner Floyd, Hwei‐Ru Tsou and Sridhar K. Rabindran. Their work appears in journals such as Cancer Research, Molecular Cancer Therapeutics, Clinical Cancer Research, Cancer Immunology Immunotherapy and Journal of Medicinal Chemistry.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.